David J. Parsley

Array ( [id] => 17052588 [patent_doc_number] => 20210262022 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-26 [patent_title] => LIVER PROTECTIVE MARC VARIANTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/807125 [patent_app_country] => US [patent_app_date] => 2020-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 81213 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16807125 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17593494 [patent_doc_number] => 20220143067 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => METHODS FOR DIAGNOSIS AND/OR THERAPY OF DISORDERS THAT CORRELATE WITH DENNDIA VARIANT 2 [patent_app_type] => utility [patent_app_number] => 17/431887 [patent_app_country] => US [patent_app_date] => 2020-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18601 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17431887 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16013731 [patent_doc_number] => 20200181708 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => MICRO-RNAS THAT MODULATE LYMPHANGIOGENESIS AND INFLAMMATORY PATHWAYS IN LYMPHATIC VESSEL CELLS [patent_app_type] => utility [patent_app_number] => 16/796576 [patent_app_country] => US [patent_app_date] => 2020-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21437 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16796576 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15994073 [patent_doc_number] => 20200172907 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-04 [patent_title] => METHOD FOR ISOLATING CROSS-REACTIVE APTAMER AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/791101 [patent_app_country] => US [patent_app_date] => 2020-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19943 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16791101 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18134940 [patent_doc_number] => 11560596 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-24 [patent_title] => Method for expecting and diagnosing UQCRB-related disease [patent_app_type] => utility [patent_app_number] => 16/784478 [patent_app_country] => US [patent_app_date] => 2020-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 21 [patent_no_of_words] => 3128 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 133 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16784478 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16422188 [patent_doc_number] => 20200347386 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => COMBINATION GENE TARGETS FOR IMPROVED IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 16/781732 [patent_app_country] => US [patent_app_date] => 2020-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65906 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16781732 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16328811 [patent_doc_number] => 20200299777 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-24 [patent_title] => Methods for Resensitizing p53-Null Cells to Cancer Chemotherapy [patent_app_type] => utility [patent_app_number] => 16/748968 [patent_app_country] => US [patent_app_date] => 2020-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7786 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16748968 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18643466 [patent_doc_number] => 11767526 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-26 [patent_title] => Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors [patent_app_type] => utility [patent_app_number] => 16/748006 [patent_app_country] => US [patent_app_date] => 2020-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 30 [patent_no_of_words] => 72408 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16748006 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18517665 [patent_doc_number] => 11707536 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-25 [patent_title] => Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A [patent_app_type] => utility [patent_app_number] => 16/743850 [patent_app_country] => US [patent_app_date] => 2020-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 29 [patent_no_of_words] => 25102 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16743850 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16341691 [patent_doc_number] => 20200306341 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => TREATMENT OF EYE DISEASE [patent_app_type] => utility [patent_app_number] => 16/738616 [patent_app_country] => US [patent_app_date] => 2020-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11165 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16738616 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17921652 [patent_doc_number] => 11464873 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-11 [patent_title] => RNA-modulating agents [patent_app_type] => utility [patent_app_number] => 16/722762 [patent_app_country] => US [patent_app_date] => 2019-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 39 [patent_no_of_words] => 17085 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16722762 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16513234 [patent_doc_number] => 20200392492 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-17 [patent_title] => Modulating Immune Responses [patent_app_type] => utility [patent_app_number] => 16/717325 [patent_app_country] => US [patent_app_date] => 2019-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10207 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16717325 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16391354 [patent_doc_number] => 20200332295 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-22 [patent_title] => APTAMERS FOR THE TREATMENT OF SICKLE CELL DISEASE [patent_app_type] => utility [patent_app_number] => 16/716570 [patent_app_country] => US [patent_app_date] => 2019-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19563 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16716570 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16222745 [patent_doc_number] => 20200247861 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-06 [patent_title] => MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES [patent_app_type] => utility [patent_app_number] => 16/707998 [patent_app_country] => US [patent_app_date] => 2019-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 187748 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16707998 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16376639 [patent_doc_number] => 20200325481 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-15 [patent_title] => ANTISENSE-BASED THERAPEUTICS FOR TARGETING HTRA1 AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/685136 [patent_app_country] => US [patent_app_date] => 2019-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24114 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16685136 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16269127 [patent_doc_number] => 20200270614 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => RNAi-BASED THERAPEUTICS FOR TARGETING HTRA1 AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/685132 [patent_app_country] => US [patent_app_date] => 2019-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18121 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16685132 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16267298 [patent_doc_number] => 20200268785 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => METHOD FOR PREVENTING ORAL CANCER [patent_app_type] => utility [patent_app_number] => 16/680374 [patent_app_country] => US [patent_app_date] => 2019-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10710 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16680374 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17299898 [patent_doc_number] => 20210395737 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => METHOD FOR REDUCING THE RISK OF A CARDIOVASCULAR EVENT WITH CONJUGATED ANTISENSE COMPOUNDS TARGETING APO(A) [patent_app_type] => utility [patent_app_number] => 17/292075 [patent_app_country] => US [patent_app_date] => 2019-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36970 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17292075 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15553373 [patent_doc_number] => 20200061098 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => CHEMICALLY MODIFIED mRNA FOR USE IN THE TREATMENT OF A DISEASE ASSOCIATED WITH THE CFTR GENE [patent_app_type] => utility [patent_app_number] => 16/673853 [patent_app_country] => US [patent_app_date] => 2019-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9668 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16673853 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16191119 [patent_doc_number] => 20200231968 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-23 [patent_title] => COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF FACTOR V [patent_app_type] => utility [patent_app_number] => 16/673865 [patent_app_country] => US [patent_app_date] => 2019-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16187 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16673865 [rel_patent_id] =>[rel_patent_doc_number] =>)